Related Experiment Videos
[Susceptibility of clinical isolates in pediatrics to cefpiramide]
Abstract:
Cefpiramide (CPM, SM-1652) had broad-spectrum antibacterial activities against most of clinically isolated organisms to which are paid attention as pathogenic organism in the field of pediatrics. Antibacterial activities of CPM against Staphylococcus aureus, Streptococcus pyogenes, Haemophilus influenzae, Bordetella pertussis and Proteus mirabilis were almost the same as those of cefoperazone (CPZ). Antibacterial activities of CPM against Escherichia coli and Klebsiella pneumoniae were somewhat weaker than those of CPZ, but antibacterial activity of CPM against Pseudomonas aeruginosa was rather stronger than that of CPZ and almost the same as that of cefsulodin. Antibacterial activity of CPM has a tendency to decrease in beta-lactamase (PCase type) producing S. aureus, E. coli, K. pneumoniae, H. Influenzae, etc. It is suggestive that the determination of not only the antibacterial activity of CPM against pathogenic organisms but also the beta-lactamase producing activity of them is important on the occasion of clinical use of CPM.
Insights
Cefpiramide exhibits broad-spectrum pediatric antibacterial activity, comparable to cefoperazone against many pathogens. Its effectiveness against Pseudomonas aeruginosa is notable, though reduced by beta-lactamase production.
Area of Science:
- Pharmacology and Microbiology
- Antimicrobial agents
- Pediatric infectious diseases
Context:
- Identification of novel antimicrobial agents is crucial for combating pediatric infections.
- Cefpiramide (CPM, SM-1652) is a cephalosporin antibiotic with potential clinical applications.
- Understanding spectrum of activity and resistance mechanisms is vital for effective therapeutic use.
Purpose:
- To evaluate the broad-spectrum antibacterial activities of Cefpiramide (CPM).
- To compare CPM's efficacy against clinically relevant pediatric pathogens with Cefoperazone (CPZ).
- To investigate the impact of beta-lactamase production on CPM's antibacterial activity.
Summary:
- Cefpiramide demonstrated broad-spectrum activity against common pediatric pathogens, including Staphylococcus aureus, Streptococcus pyogenes, Haemophilus influenzae, Bordetella pertussis, and Proteus mirabilis, with efficacy similar to cefoperazone.
- CPM showed slightly reduced activity against Escherichia coli and Klebsiella pneumoniae compared to CPZ, but exhibited enhanced activity against Pseudomonas aeruginosa, comparable to cefsulodin.
- Antibacterial activity of CPM was diminished in beta-lactamase producing strains of S. aureus, E. coli, K. pneumoniae, and H. influenzae, highlighting the importance of assessing beta-lactamase activity.
Impact:
- Clinical utility of Cefpiramide necessitates consideration of both its intrinsic antibacterial spectrum and the beta-lactamase producing capacity of target pathogens.
- CPM represents a potential therapeutic option for pediatric infections, particularly those caused by Pseudomonas aeruginosa.
- This study underscores the importance of antimicrobial susceptibility testing, including beta-lactamase detection, for optimizing Cefpiramide treatment strategies.